New Genetic Causes for Autoimmune Neonatal Diabetes Identified
Researchers have identified new genetic causes for autoimmune neonatal diabetes, a rare condition diagnosed within the first six months of life. The study, conducted by the University of Exeter and international collaborators, found that DNA changes in two non-coding genes, RNU4ATAC and RNU6ATAC, can lead to the disease. These genes produce functional RNA molecules rather than proteins and were observed to disrupt approximately 800 other genes, many related to the immune system.
Unveiling New Genetic Origins
Scientists from the University of Exeter, in collaboration with international partners, have identified novel genetic origins for neonatal diabetes. This rare form of diabetes manifests within the initial six months of an infant's life and is caused by genetic factors. The research focused on non-coding regions of the human genome, an area previously less explored in genetic disease studies compared to protein-coding genes.
Discovery of Genetic Causes
The study revealed that alterations in two specific non-coding genes, RNU4ATAC and RNU6ATAC, are responsible for autoimmune neonatal diabetes. Unlike typical genes that code for proteins, RNU4ATAC and RNU6ATAC produce functional RNA molecules. These RNA molecules play roles in gene regulation and the interpretation of genetic information.
The research identified these genetic alterations in 19 children diagnosed with autoimmune neonatal diabetes, who were part of a global program offering genetic testing for suspected genetic forms of the condition.
"Alterations in two specific non-coding genes, RNU4ATAC and RNU6ATAC, produce functional RNA molecules and are responsible for autoimmune neonatal diabetes."
Widespread Gene Disruption and Immune System Impact
The affected children exhibited an autoimmune form of diabetes, characterized by the immune system targeting and attacking insulin-producing beta cells. This mechanism is comparable to that observed in Type 1 diabetes.
Laboratory and computational analyses indicated that the mutations in RNU4ATAC and RNU6ATAC disrupted the function of approximately 800 other genes, with many of these genes having associations with the immune system.
The mutations in RNU4ATAC and RNU6ATAC were found to disrupt the function of approximately 800 other genes, many linked to the immune system.
Research Methodology
The team utilized genome sequencing to identify the genetic changes. Further investigations, which included combining DNA sequencing with the analysis of patient blood samples, provided insights into how these DNA changes impact cellular function and contribute to the development of diabetes. The study received support from the NIHR Exeter Biomedical Research Centre and Clinical Research Facility.
Implications for Diagnosis and Treatment
This discovery underscores the significance of non-protein coding genes in the development of human diseases. It offers potential new diagnostic pathways for individuals and families affected by rare conditions that currently lack a definitive genetic diagnosis. Understanding these specific genetic origins is anticipated to inform the development of new treatments and enhance care for patients with neonatal diabetes.
Furthermore, the findings contribute to a deeper understanding of the biological pathways that lead to autoimmune diabetes. Researchers suggest that one or more of the 800 disrupted genes could be central to the pathogenesis of autoimmune diabetes, potentially uncovering new biological mechanisms and targets for drug development, including for the more common Type 1 diabetes. The rarity of this specific genetic condition also provides an opportunity to study the developmental pathways of autoimmune diabetes.
This discovery offers potential new diagnostic pathways and is anticipated to inform the development of new treatments and enhance care for patients with neonatal diabetes.
Publication and Presentation
The study, titled "Bi-allelic variants in the non-protein-coding minor spliceosome components RNU6ATAC and RNU4ATAC cause syndromic monogenic autoimmune diabetes," was published in the American Journal of Human Genetics. It is also scheduled for presentation at the European Society of Human Genetics conference.